Skip to main content

Table 1 The characteristics of the children included in the model group (n = 162) and in the validation group (n = 205).

From: The first-year growth response to growth hormone treatment predicts the long-term prepubertal growth response in children

  Model group
(30 girls, 132 boys)
Validation group
(58 girls, 147 boys)
Variables Median Min Max n Median Min Max n
At birth         
Gestational age (weeks) 40 37 42 162 40 37 42 205
Height at birth SDS -1.07 -2.65 2.6 162 -1.48 -5.75 1.9 205
Weight at birth SDS -0.88 -2.75 3.24 162 -1.28 -4.5 1.81 205
At GH start         
Age at start of GH treatment (yrs) 8.3 2.78 13.92 162 7.78 2.51 12.53 205
Height SDS -2.91 -4.59 -1.54 162 -2.84 -4.76 -1.29 205
Weight SDS -2.58 -4.29 0.73 162 -2.5 -5.28 1.28 205
Weight for height SDS -0.54 -3.31 3.85 162 -0.61 -3.08 4.09 205
Body mass index (kg/m2) 15.4 12.88 23.98 162 15.19 12.25 23.76 205
Change in height SDS during pre-treatment year 0.02 -0.85 0.58 144 0.01 -0.71 0.68 186
Target height SDS -0.75 -2.4 1.26 162 -0.66 -2.71 0.94 205
Fathers height SDS -1.13 -4.93 1.91 162 -0.83 -3.86 2.02 205
Mothers height SDS -1,25 -3.55 1.22 162 -1.25 -3.55 1.55 205
Diff MPH SDS -2.26 -4.98 -0.8 162 -2.27 -5.11 -0.41 205
GHmax during AITT (mU/L) 19.8 1.7 229.4 160 21 2.4 124.88 181
GHmax of 24 h profile (mU/L) 34.65 3.88 81.08 64 32.8 7.55 235.37 94
IGF-I at GH start 96.25 11.68 219 68 80 8 330 150
IGF-I SDS -0.6 -6.69 1.38 68 -1.1 -7.43 3.03 150
GH dose (ug/kg.day) 0.033 0.027 0.04 162 0.033 0.023 0.043 205
During treatment         
Change in height SDS first yr 0.72 0.3 2.26 162 0.74 0.07 2.56 205
Change in height SDS during 2 yrs 1.15 0.4 2.88 162 1.14 0.23 3.12 205
  1. Growth hormone (mU/L) levels were analysed at GP-GRC, GU, with Delfia monoclonal assay, Wallac, Finland, standard WHO IRP 80/505, [8].
  2. Insulin-like growth factor I (IGF-I) (μg/L) were analysed according to Blum and Breier [26] and transformed into SD scores (SDS) according to gender and age of our prepubertal reference [27].